• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Pain Management Treatment Markets - Product Image

Pain Management Treatment Markets

  • ID: 2497102
  • March 2013
  • Region: Global
  • 144 Pages
  • TriMark Publications

FEATURED COMPANIES

  • Abbott (AbbVie)
  • Astellas
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • Purdue Pharma
  • MORE

Pain management describes a particular set of drugs, analgesics, which are specifically used as therapeutics to control pain in the clinic. As pain affects 1.5 billion people worldwide, these drugs are one of the major segments of the central nervous system (CNS) therapies market. This TriMark Publications report focuses on the role of pain management drugs in clinical use and in drug development for acute pain, chronic pain, neuropathic path and nociceptive pain. The report discusses drug development and targeted therapeutics, as well as their use in clinical trials. New approaches meant to aid in development of drugs for therapeutic use are emphasized.

The study also analyzes almost all of the major, specialty and emerging companies known to be marketing, manufacturing or developing pain management treatment products in the U.S. and worldwide. Additionally, this review provides detailed tables, charts and figures with past and projected sales data for the U.S., Europe and other geographic regions.

FEATURED COMPANIES

  • Abbott (AbbVie)
  • Astellas
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • Purdue Pharma
  • MORE

1. Overview
1.1 Statement of Report
1.2 About this Report
1.3 Scope of the Report
1.4 Objectives
1.5 Methodology
1.6 Executive Summary

2. Introduction
2.1 Overview of Pain
2.1.1 Acute Pain
2.1.2 Chronic Pain
2.1.3 Neuropathic Pain
2.1.4 Nociceptive Pain
2.2 Current Treatment Approaches
2.3 Key Problems
2.3.1 Side Effects of Therapy
2.3.2 Abuse Issues
2.4 The Need for New Treatments

3. Market Overview
3.1 Introduction
3.2 Market Analysis
3.3 Therapeutic Class
3.3.1 Opioids
3.3.2 NSAIDs
3.3.3 Local Anesthetics
3.3.4 Antidepressants
3.3.5 Anticonvulsants
3.4 Geographical Analysis
3.4.1 U.S.
3.4.2 Europe
3.4.3 Japan
3.5 Key Players

4. Pipeline Analysis
4.1 Introduction
4.2 Pain
4.3 Neuropathic Pain
4.4 Novel Therapeutic Approaches
4.4.1 CGRP Antagonists
4.4.2 CB2 Agonists
4.4.3 Sodium Channel Modulators
4.4.4 Calcium Channel Modulators
4.4.5 NMDA Antagonists
4.4.6 P2x Receptors
4.4.7 Trp Channels
4.5 Unsuccessful Targets
4.5.1 TrpV1 blockers
4.5.2 FAAH Inhibitors
4.5.3 Other Targets
4.6 Novel Formulations
4.6.1 Novel Opioids
4.6.2 Extended Release Formulations
4.6.3 Transdermal Formulations
4.6.4 Other Routes
4.6.5 Drug Combinations
4.7 Overview

5. The Changing Competitive Landscape
5.1 Overview
5.2 The Exit of Major Companies
5.3 Major Pharma Players
5.3.1 Abbott (AbbVie)
5.3.2 Astellas
5.3.3 Eli Lilly
5.3.4 Johnson & Johnson
5.3.5 Novartis
5.3.6 Pfizer
5.4 Pain Specialty Companies
5.4.1 Cephalon (Teva)
5.4.2 Endo Pharmaceuticals
5.4.3 Grunenthal
5.4.4 Hospira
5.4.5 Purdue Pharma
5.4.6 Mallinckrodt
5.5 Emerging Biotechs
5.5.1 AcelRx
5.5.2 Acura Pharmaceuticals
5.5.3 Afferent Pharmaceuticals
5.5.4 Algiax Pharmaceuticals
5.5.5 Arcion Therapeutics
5.5.6 BioDelivery Sciences International
5.5.7 Cara Therapeutics
5.5.8 Convergence Pharmaceuticals
5.5.9 Cytogel Pharma
5.5.10 DURECT
5.5.11 Egalet a/s
5.5.12 iMed
5.5.13 KemPharm
5.5.14 NeurAxon
5.5.15 NeurogesX
5.5.16 Newron Pharmaceuticals
5.5.17 Nuvo Research
5.5.18 Pacira Pharmaceuticals
5.5.19 Pain Therapeutics
5.5.20 QRx Pharma
5.5.21 Relmada Therapeutics
5.5.22 Relevare Pharmaceuticals
5.5.23 Spinifex Pharma
5.5.24 Xenon Pharma
5.5.25 Xenoport
5.5.26 Zalicus
5.5.27 Zogenix

6. Market Outlook
6.1 Overview
6.2 Increased Demand
6.3 The Continued Impact of Generics
6.4 Key Patent Expirations
6.5 Key New Launches
6.5.1 2012
6.5.2 2013
6.5.3 2014
6.5.4 2015
6.6 Overall Assessment
6.7 Market Forecast
6.7.1 Opioids
6.7.2 Neuropathic Pain
6.7.3 Migraine
6.7.4 Fibromyalgia
6.8 Geographical Analysis
6.8.1 U.S.
6.8.2 Europe
6.8.3 Japan
6.9 Conclusions

7. Company Profiles

Glossary

Bibliography

INDEX OF TABLES

Table 2.1: Treatment Recommendations for Osteoarthritic Pain
Table 2.2: Competitive Landscape for Postoperative Pain Management
Table 2.3: A Suggested Stepwise Approach to Treating Neuropathic Pain
Table 2.4: EULAR Recommendations for Treating Fibromyalgia
Table 2.5: Remoxy Versus OxyContin OC
Table 3.1: Branded Opioid Formulations and their Estimated 2012 Sales
Table 3.2: The More Widely Used NSAIDs
Table 3.4: 2012 U.S. Sales of Branded Triptan Containing Products for Migraine Pain
Table 4.1: NCEs in Advanced Clinical Development for the Treatment of Pain
Table 4.2: CGRP Antagonists in Development for the Treatment of Migraine
Table 4.3: Cannabinoid Receptor Agonists that are or have been in Development
Table 4.4: Sodium Channel Blockers in Development for Pain Indications
Table 4.5: Calcium Channel Blockers in Active Development for the Treatment of Pain
Table 4.6: NMDA Antagonists in Development for the Treatment of Pain
Table 4.7: P2x Channel Blockers in Active Development for the Treatment of Pain
Table 4.8: Active TrpV3 and TrpV4 Modulator Programs
Table 4.9: TrpA1 Blockers Reported to be in Active Development
Table 4.10: TrpM Channel Blockers Reported to be in Active Development
Table 4.11: TrpV1 Blockers Identified for Development in the Treatment of Pain
Table 4.12: FAAH Inhibitors Being Developed for Pain Indications
Table 4.13: Novel Approaches to the Treatment of Pain
Table 4.14: Novel Opioid Formulations in Development for the Treatment of Pain
Table 4.15: Novel Combination Formulations in Development for the Treatment of Pain
Table 6.1: Market Drivers for the Pain Management Therapeutics Market
Table 6.2: Market Impediments for the Pain Management Therapeutics Market
Table 6.3: Status of Potential New Treatments for Neuropathic Pain

INDEX OF FIGURES

Figure 2.1: The Diverse Forms of Neuropathic Pain
Figure 2.2: The WHO-Recommended Treatment Ladder for Pain
Figure 2.3: Approved Treatment Options for Neuropathic Pain
Figure 2.4: Opioid Abuse and Emergency Eepartment Visits in the U.S., 2004 to 2008
Figure 2.5: Trends in Drug Abuse-Related ED Visits Involving Hydrocodone and Oxycodone, Coterminous U.S., 1994-2002
Figure 2.6: Opioid Plasma Concentration Versus Time, 'Bolus Effect'
Figure 2.7: OxyContin Original (OC) and Reformulated (OP)
Figure 2.8: How Remoxy Hinders Potential Drug Abuse
Figure 2.9: The Effect of Corporate Changes on Remoxy and Pain Therapeutics
Figure 2.10: Tamper Proofing with the Embeda Formulation
Figure 2.11: How Embeda Works
Figure 3.1: The Pain Market 2012, Segmentation by Therapeutic Class
Figure 3.2: Breakdown of 2012 Opioid Sales by Drug
Figure 3.3: The Leading NSAIDs and their Market Share in 2012
Figure 3.4: U.S. Sales of Opioid Products in 2012 by Volume
Figure 3.5: The U.S. Neuropathic Pain Market in 2012
Figure 3.6: The U.S. Fibromyalgia Pain Market in 2012
Figure 3.7: The 2012 Pain Market, Segmentation by Company
Figure 4.1: Novel Approaches to the Treatment of Pain
Figure 4.2: Pfizer?s NCEs in Development for Pain in October 2008
Figure 4.3: Potential Targets for Treating Neuropathic Pain
Figure 6.1: Anticipated New Product Launches 2012-2015
Figure 6.2: Forecast Segmentation of the Pain Market in 2018
Figure 6.3: Forecast Breakdown of U.S. Neuropathic Pain Market in 2018
Figure 6.4: Geographic Distribution of the Acute and Chronic Pain Market in 2018
Figure 6.5: Geographic Distribution of the Migraine Market in 2018
Figure 6.6: Geographic Distribution of the Fibromyalgia Market in 2018
Figure 6.7: Geographic Distribution of the Neuropathic Pain Market in 2018

- Abbott (AbbVie)
- AcelRx
- Acura Pharmaceuticals
- Afferent Pharmaceuticals
- Algiax Pharmaceuticals
- Arcion Therapeutics
- Astellas
- BioDelivery Sciences International
- Cara Therapeutics
- Cephalon (Teva)
- Convergence Pharmaceuticals
- Cytogel Pharma
- DURECT
- Egalet a/s
- Eli Lilly
- Emerging Biotechs
- Endo Pharmaceuticals
- Grunenthal
- Hospira
- Johnson & Johnson
- KemPharm
- Mallinckrodt
- NeurAxon
- NeurogesX
- Newron Pharmaceuticals
- Novartis
- Nuvo Research
- Pacira Pharmaceuticals
- Pain Specialty Companies
- Pain Therapeutics
- Pfizer
- Purdue Pharma
- QRx Pharma
- Relevare Pharmaceuticals
- Relmada Therapeutics
- Spinifex Pharma
- Xenon Pharma
- Xenoport
- Zalicus
- Zogenix
- iMed

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos